Ying Li counsels biotechnology and pharmaceutical clients on patent portfolio management and strategic development. She has extensive experience in patent prosecution worldwide. Ying helps clients survey competitive patent landscapes and renders opinions of counsel on freedom to operate, non-infringement, and patent invalidity. She also conducts IP due diligence for venture capital investment and corporate business development.
Ying has worked on a wide range of therapeutic areas including cancer and immune disorders, with particular experience in biologics such as antibody therapeutics, as well as molecular diagnostics, vaccines, and RNA interference. She assists clients with pre-litigation strategy counseling and freedom to operate analyses concerning application of the Biologics Act to biotherapeutic development programs.
Ying also has extensive experience in contentious matters before US and foreign patent offices, and has represented clients in matters related to transgenic animals and immune molecules. She successfully argued for an interference appellee before the Court of Appeals for the Federal Circuit in a case of first impression related to conception of recombinant DNA.
During her doctoral research, Ying discovered a novel gene involved in DNA double-stranded break repair and antibody gene rearrangement.
- New York
- US District Court, Eastern District of New York
- US District Court, Southern District of New York
- US Court of Appeals, Federal Circuit
- US Patent & Trademark Office
- J.D., Fordham University School of Law, 2002, cum laude; Order of the Coif; The Senior Prize
- Ph.D., Harvard University, 1996, Immunology
- B.A., Smith College, 1990, magna cum laude; with Highest Honors in Biochemistry
"Pitfalls for US Applicants When Filing Patent Applications at the EPO," 2019 BIO International Convention, Philadelphia, PA, June 2019
"Patent Portfolio Mangement in Light of Life Techs. v. Promega and Extraterritorial Reach of US Patents," 8th Annual Summit on Biosimilars, American Conference Institute, June 2017
"Immunotherapy: a Patent Perspective," World Gene Congress, Shanghai, China, November 2016
"Biosimilars: A Patent Perspective," Licensing Executives Society of New Jersey, October 2015
"Patent Prosecution from a US Perspective," the European Patent Office, Munich, Germany, March 2012
"Mayo v. Prometheus and Its Implications in the Biotech Industry," New York Intellectual Property Law Association Forum, 2012
News & Publications
July 19, 2019
September 29, 2017
February 10, 2016
September 28, 2017
- IAM Patent 1000, Prosecution: New York (2019)